<code id='8E145BF669'></code><style id='8E145BF669'></style>
    • <acronym id='8E145BF669'></acronym>
      <center id='8E145BF669'><center id='8E145BF669'><tfoot id='8E145BF669'></tfoot></center><abbr id='8E145BF669'><dir id='8E145BF669'><tfoot id='8E145BF669'></tfoot><noframes id='8E145BF669'>

    • <optgroup id='8E145BF669'><strike id='8E145BF669'><sup id='8E145BF669'></sup></strike><code id='8E145BF669'></code></optgroup>
        1. <b id='8E145BF669'><label id='8E145BF669'><select id='8E145BF669'><dt id='8E145BF669'><span id='8E145BF669'></span></dt></select></label></b><u id='8E145BF669'></u>
          <i id='8E145BF669'><strike id='8E145BF669'><tt id='8E145BF669'><pre id='8E145BF669'></pre></tt></strike></i>

          leisure time

          leisure time

          author:entertainment    Page View:77
          Primary care exam 01
          ReCor Medical, a startup owned by Japanese company Otsuka Medical Devices, and Medtronic have run studies that showed renal denervation leads to a modest decrease in blood pressure. Adam Berry/Getty Images

          The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy.

          Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome. The therapy, which is meant to be a one-time procedure, is administered via a catheter. Electrodes on the catheter then emit radiofrequency or ultrasound energy to block nerve signals from the kidneys that increase blood pressure.

          advertisement

          The therapy, a simple procedure to reduce the blood pressure of millions of Americans, was once seen as a boon for cardiologists and device makers. But a large-scale clinical trial from Medtronic in 2014 called renal denervation’s efficacy into question, as it did not significantly reduce blood pressure compared to placebo treatments.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Google and Epic fight stronger regulation of AI in health care
          Google and Epic fight stronger regulation of AI in health care

          AdobeBigbusinessespoisedtoprofitfromtheadvanceofartificialintelligenceinhealthcarearepushingbackagai

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          Pharma companies must ensure equitable access to obesity drugs

          TheobesitydrugWegovyisseenatapharmacyinChicago.ScottOlson/GettyImagesWeightlosstreatmentshavethepote